baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

DKSH N/ CH0126673539 /

5/23/2024 4:34:03 PM	Chg. -0.20	Volume	Bid4:50:23 PM	Ask4:50:23 PM	Market Capitalization	Dividend Y.	P/E Ratio
61.30CHF	-0.33%	27,154 Turnover: 1.68 mill.	61.20Bid Size: 864	61.40Ask Size: 306	3.99 bill.CHF	3.67%	21.89

GlobeNewswire 5/21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 5/21 Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...

GlobeNewswire 5/21 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

GlobeNewswire 5/13 Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (...

GlobeNewswire 5/2 Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

GlobeNewswire 4/30 U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...

GlobeNewswire 4/24 Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...

GlobeNewswire 4/19 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 4/16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 4/3 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire 3/22 Alvotech Announces Increase in Number of Own Shares

GlobeNewswire 3/20 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire 3/5 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

GlobeNewswire 2/29 Alvotech Appoints Interim Chief Quality Officer

GlobeNewswire 2/26 Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...

GlobeNewswire 2/24 Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...

GlobeNewswire 2/15 Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

GlobeNewswire 1/29 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...

GlobeNewswire 1/19 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

GlobeNewswire 1/10 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

GlobeNewswire 1/3 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...

GlobeNewswire 11/29/2023 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...

GlobeNewswire 11/28/2023 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

GlobeNewswire 11/21/2023 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...

GlobeNewswire 11/14/2023 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...

DKSH N/ CH0126673539 /

If you wish to receive reply to your feedback, please provide your email address.